IP Library › Granted Patent US 12,679,834
Granted Patent B2
US 12,679,834 · App. 18/506,164 · Granted Jul 14, 2026

Bicyclic compounds and their uses

Inventors: Vincent Bordas (Village-Neuf, FR); Jvan Brun (Muttenz, CH); Markus Furegati (Allschwil, CH); Wanben Gong (Suzhou, CN); Jacques Hamon (Habsheim, FR); Jürgen Hans-Hermann Hinrichs (Schopfheim, DE); Philipp Holzer (Sissach, CH); Fatma Limam (Strasbourg, FR); Henrik Möbitz (Arlesheim, CH); Sandro Nocito (Wölflinswil, CH); Simone Plattner (Weil am Rhein, DE); Niko Schmiedeberg (Riehen, CH); Joseph Schoepfer (Riehen, CH); Ross Sinclair Strang (Hagenthal-le-Bas, FR); Shuping Yao (Suzhou, CN); Huangchao Yu (Suzhou, CN); Frédéric Zecri (Brookline, MA); Sisi Zhang (Suzhou, CN)
Assignee: NOVARTIS AG
C07D413/14C07D401/14C07D405/14C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,679,834
App. No.
18/506,164
Filed
Nov 10, 2023
Granted
Jul 14, 2026
Kind
B2
Art Unit
1627
USPC
514/256
Abstract

The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 26 , R 27 , y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

Claims (28)

1 . A compound, or a salt thereof, of formula A or formula B:

wherein

R 1 is selected from:

R 2 is selected from:

R 3 is (C 1 -C 2 )alkyl unsubstituted or substituted by 1, 2 or 3 substituents independently selected from halo and OH,

R 26 is CH 3 or H,

R 27 is H,

R 5 is CH 3 , or alternatively, two R 5 groups on adjacent carbon atoms join, along with the carbon atoms to which they are attached, to form a fused cyclobutyl ring,

y is 0, 1, or 2,

Y is N or CH, and

PG 1 is a protecting group.

2 . The compound of claim 1 , or a salt thereof, which is:

or a salt thereof.

3 . The compound of claim 1 , or a salt thereof, wherein PG 1 is BOC.

4 . The compound of claim 3 , or a salt thereof, which is:

or a salt thereof.

5 . The compound of claim 1 , or a salt thereof, wherein R 1 is

6 . The compound of claim 1 , or a salt thereof, wherein R 1 is

7 . The compound of claim 1 , or a salt thereof, wherein R 2 is

8 . The compound of claim 1 , or a salt thereof, wherein R 2 is

9 . The compound of claim 1 , or a salt thereof, wherein R 3 is (C 1 -C 2 )alkyl.

10 . The compound of claim 1 , or a salt thereof, wherein R 3 is —CH 2 CH 3 .

11 . The compound of claim 1 , or a salt thereof, wherein R 26 is H.

12 . The compound of claim 1 , or a salt thereof, wherein R 5 is CH 3 .

13 . The compound of claim 1 , or a salt thereof, wherein two R 5 groups on adjacent carbon atoms join, along with the carbon atoms to which they are attached, to form a fused cyclobutyl ring.

14 . The compound of claim 1 , or a salt thereof, wherein y is 0.

15 . The compound of claim 1 , or a salt thereof, wherein Y is N.

16 . The compound of claim 1 , or a salt thereof, wherein PG 1 is BOC, para-methoxybenzyl, or benzyl.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 065567/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: BORDAS, VINCENT; BRUN, JVAN; HAMON, JACQUES; HINRICHS, JUERGEN HANS-HERMANN; HOLZER, PHILIPP; MOEBITZ, HENRIK; PLATTNER, SIMONE; SCHMIEDEBERG, NIKO; SCHOEPFER, JOSEPH; STRANG, ROSS
To: NOVARTIS PHARMA AG
Reel/Frame 065567/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 065567/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: GONG, WANBEN; YAO, SHUPING; YU, HUANGCHAO; ZHANG, SISI
To: SUZHOU NOVARTIS TECHNICAL DEVELOPMENT CO., LTD.
Reel/Frame 065567/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: SUZHOU NOVARTIS TECHNICAL DEVELOPMENT CO., LTD.
To: NOVARTIS AG
Reel/Frame 065568/0008 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: ZECRI, FREDERIC
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 065568/0023 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 065568/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: ZECRI, FREDERIC
To: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
Reel/Frame 065568/0036 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 065568/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: GONG, WANBEN; YAO, SHUPING; YU, HUANGCHAO; ZHANG, SISI
To: SUZHOU NOVARTIS TECHNICAL DEVELOPMENT CO., LTD.
Reel/Frame 065568/0083 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: SUZHOU NOVARTIS TECHNICAL DEVELOPMENT CO., LTD.
To: NOVARTIS AG
Reel/Frame 065568/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2023
From: BORDAS, VINCENT; BRUN, JVAN; DECKER, ANDREA; FUREGATI, MARKUS; GOGNIAT, GEOFFREY; HAMON, JACQUES; HINRICHS, JUERGEN HANS-HERMANN; HOLZER, PHILIPP; LIMAM, FATMA; MOEBITZ, HENRIK; NOCITO, SANDRO; PLATTNER, SIMONE; SCHMIEDEBERG, NIKO; SCHOEPFER, JOSEPH; SOTO, JESSICA; STRANG, ROSS
To: NOVARTIS PHARMA AG
Reel/Frame 065580/0732 →
Continuity (2)
Division 17824407 · May 25, 2022
Related Publication 20240360118A1 · Oct 31, 2024
References Cited (41)
US 11878973B2 · Bordas et al. · 2024 [cited by applicant]
US 20160002247A1 · Nagano et al. · 2016 [cited by examiner]
US 20230046859A1 · Bordas et al. · 2023 [cited by applicant]
CN 112409331A · 2021 [cited by applicant]
CN 112778311A · 2021 [cited by applicant]
WO 2008027990A1 · 2008 [cited by applicant]
WO 2008057601A2 · 2008 [cited by applicant]
WO 2010093436A2 · 2010 [cited by applicant]
WO 2013174931A1 · 2013 [cited by applicant]
WO 2017025416A1 · 2017 [cited by applicant]
WO 2018229683A1 · 2018 [cited by applicant]
WO 2019016772A2 · 2019 [cited by applicant]
WO 2019236448A1 · 2019 [cited by applicant]
WO 2019241802A2 · 2019 [cited by applicant]
WO 2020033413A2 · 2020 [cited by applicant]
WO 2020041756A1 · 2020 [cited by applicant]
WO 2022008419A1 · 2022 [cited by applicant]
WO 2022076403A1 · 2022 [cited by applicant]
WO 2022249060A1 · 2022 [cited by applicant]
Aggarwal, et al., Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress, PNAS, Jan. 25, 2011, 1525-1530, 108(4). [cited by applicant]
Lizardo, et al., Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside, BBA—Reviews on Cancer, Oct. 6, 2020, 188447, 1874. [cited by applicant]
Lorenzi, et al., Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review, Journal of Oncology, 2020, Article ID 1807929, 2020. [cited by applicant]
Picco, et al., Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy, Cancer Discovery, Aug. 2021, 1923-1937… [cited by applicant]
Aguiar, et al., Effect of polymorphism on the absorption of Chloramphenicol from Chloramphenicol Palmitate, Journal of Pharmaceutical Sciences, 56(7), 847-853, 1967. [cited by applicant]
Akhapkina, et al., Fundamental Principles of the Modulator Concept and Classification of Modulator Drugs, RMZh, 19, 933-951, 2012. [cited by applicant]
Belikov, Relationship between the chemical structure, properties of compounds and their action on the body, Pharmaceutical Chemistry, chapters 1.1, 1.2, 2.5, 2.6, 2.7, 11, 27-29, 2007. [cited by applicant]
Byrn, et al., Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations, Pharmaceutical Research, 12(7), 945-954, 1995. [cited by applicant]
Caira, Crystalline Polymorphism of Organic Compounds, Topics in Current Chemistry, 198, 163-208, 1998. [cited by applicant]
Chou, Drug Combination Studies and their Synergy Quantification using the Chou-Talalay Method, Cancer Research, 70(2), 440-446, Jan. 15, 2010. [cited by applicant]
Dyson, et al., Chemistry of Synthetic Drugs, 12-19, 1964. [cited by applicant]
Einfalt, et al., Methods of amorphization and investigation of the amorphous state, Acta Pharmaceutica, 63, 305-334, 2013. [cited by applicant]
Gavrilov, Pharmaceutical Engineering. Manufacture of Drugs, 20, 2010. [cited by applicant]
Kearns, et al., Developmental Pharmacology—Drug Disposition, Action, and Therapy in Infants and Children, The New England Journal of Medicine, 349(12), 1157-1167, Sep. 18, 2003. [cited by applicant]
Kharkevich, Doses and concentrations, Pharmacology, 10, 72-82, 2010. [cited by applicant]
Kholodov L.E., Clinical Pharmacokinetics, Medicine, 83-98; 134-138; 160; 378-380, 1985, Moscow. [cited by applicant]
Knunyants, Chemical Encyclopedia, 167, 1990. [cited by applicant]
Kuznetsova, High-resolution X-Ray Analysis, Irkutsk State University, 2005. [cited by applicant]
Pokrovsky, Antitumor Agents, Small Medical Encyclopedia, 5, 90-96, 1996. [cited by applicant]
Sergeev, A concise course in molecular biology, 10, 1975. [cited by applicant]
Smith, et al., Organic synthesis, Science and Art, 64, 2001. [cited by applicant]
Yu, Amorphous pharmaceutical solids: preparation, characterization and stabilization, Advanced Drug Delivery Reviews, 48, 27-42, 2001. [cited by applicant]